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the questionnaire in each country, and comparability of
data across countries.
PKU4
LINGUISTIC VALIDATION OF THE
KING’S HEALTH QUESTIONNAIRE (KHQ) IN 
EIGHT LANGUAGES
Conway K1, Uzun V1, Marrel A2, Cardozo L3, Kelleher C4, 
Haye I5
1Mapi Research Institute, Lyon, France; 2Mapi Values, Lyon, 
France; 3King’s College Hospital, London, UK; 4St Thomas’ 
Hospital, London, UK; 5Pharmacia & Upjohn, St. Quentin en 
Yvelines, France
OBJECTIVES: While measurement of quality of life
(QoL) has become a vital part of assessing urinary incon-
tinence in women, linguistically validated language ver-
sions of a measure including questions on QoL, strategies
for coping and the severity of symptoms has not been
available. Prior to use in an international trial, the King’s
Health Questionnaire (KHQ) designed in UK English had
to undergo cross-cultural adaptation in eight languages. 
METHODS: The translation process of the KHQ, coor-
dinated by a QoL specialist in each target country, em-
ployed the following methodology: 1) two forward trans-
lations by professional translators, native speakers of the
target language and fluent in English; 2) comparison and
reconciliation of the translations by QoL specialist and
translators; 3) backward translation by a native English
speaker; 4) comparison of source and backward version;
5) comprehension test in a sample target population; 6)
international harmonization. 
RESULTS: Linguistic and conceptual issues emerged when
translating idiomatic English phrases and the original re-
sponse scales. No linguistic equivalent was available for
idiomatic expressions such as “waterworks infection” or
“make you feel bad about yourself” and the term “blad-
der” was revealed as being too technical during compre-
hension tests. Patient testing also showed that a response
option “not applicable” was lacking for certain questions.
To harmonize with the validated original however, no
changes were made in the response categories. 
CONCLUSIONS: A rigorous translation methodology
was performed to ensure conceptual equivalence and
cross-cultural acceptability of translations. Psychometric
testing will be conducted to ensure reliability and validity
in each translation. This work highlights the value of in-
tegrating international feedback into instrument design.
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ACUTE REJECTION EPISODES ARE 
ASSOCIATED WITH HIGHER UTILIZATION 
OF RESOURCES AFTER 
KIDNEY TRANSPLANTATION
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Sirolimus (rapamycin), in combination with standard im-
munosuppressive therapy, significantly reduced the inci-
dence of acute rejection (AR) in a prospective trial in kid-
ney transplant recipients. The purpose of this study was
to determine the relationship between resource utilization
and the number of AR episodes. 
METHODS: Medical resource utilization data were col-
lected for 719 US patients enrolled in a randomized, dou-
ble-blind, controlled clinical trial. Patients were catego-
rized into three groups according to their experience of
AR (both biopsy confirmed and presumptive) during the
first 6 months post transplant: those who had no AR
(N  542), one AR episode (N  125), and two or more
AR episodes (N  52). Measures of medical resource uti-
lization were compared between groups. The measures
included mean hospital days, days on dialysis, and
amount of concomitant immunosuppressive rescue medi-
cations. Different immunosuppressive rescue drugs were
combined into a single measure in the analysis using cost
estimates based on average wholesale prices. 
RESULTS: Patients experiencing one AR episode had
higher resource utilization rates (18.8 hospital days, 10.6
days on dialysis, and $10,600 cost of concomitant immu-
nosuppressive rescue drugs) compared with those experi-
encing none (12.6 hospital days, 1.7 days on dialysis, and
$1400 of rescue drugs). Patients with multiple AR epi-
sodes had the highest rates of resource utilization (20.5
days of hospitalization, 10.4 days on dialysis, and $16,600
of concomitant immunosuppressive rescue drugs). All
three-way differences were significant at the .05 level
based on F-tests. 
CONCLUSIONS: AR episodes in kidney transplant pa-
tients were associated with higher utilization of resources
during the first six months post-transplantation. A reduc-
tion in the AR rate by sirolimus may offer both improved
economic as well as clinical outcomes.
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OBJECTIVE: A cost-effectiveness analysis comparison of
mycophenolate mofetil, a new immunosuppressant, and
muromonab CD3 in patients with intractable acute rejec-
tion after renal transplantation was conducted. 
METHODS: A clinical decision analytic model was cre-
ated based upon their use in Nagoya Second Red Cross
Hospital. This study was analyzed from the payer’s per-
spective. The cost data were obtained from the center
based on what would be paid to the hospital according to
the Health Insurance Price of April 1996. The survival of
the graft at 90 days was used as an effectiveness endpoint
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and the graft survival rate data was obtained from the
clinical studies of both drugs in Japan. 
RESULTS: Expected cost-effectiveness ratios per graft
surviving at 90 days were $13,730 ($1  120 Yen) for
mycophenolate mofetil, and $29,060 for muromonab
CD3 for the baseline analysis. Thus, a $12,400 cost-savings
of mycophenolate mofetil was observed. Comprehensive
sensitive analyses were done, such as drug efficacy rate in
the initial treatment, rejection rate after the initial treat-
ment, and graft loss rate. However, the cost-saving by my-
cophenolate mofetil continued to be found for all of these
cases so that the model can be considered to be robust. 
CONCLUSIONS: Mycophenolate mofetil treatment
proved to be cost-effective in comparison with muromonab
CD3 for intractable acute rejection in renal transplantation.
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OBJECTIVE: The purpose of this study was to analyze
the cost-utility ratios of liver and kidney transplantations
in a German transplant centre. 
METHOD: Sixty patients with liver transplantation and
77 patients with kidney transplantation were included in
a full cost assessment based on process costs with differ-
ent cost drivers (e.g., patient days, dialysis treatments,
admission) and based on the friction cost method to cal-
culate indirect costs. Benefits of transplantation were as-
sessed employing the EuroQol quality of life instrument
(German version). Both costs and benefits were dis-
counted with a discount rate of 5%. Several sensitivity
analyses were performed. 
RESULTS: Discounted with 5% and with a time horizon
of 20 years dialysis patients could gain 0.76 quality-
adjusted life-years (QALYs). Liver transplant recipients
gained 3.85 QALYs. The cost per QALYs gained ratio is
76,800 DM for liver transplantation. Gross cost per
QALY of dialysis patients is 147,800 DM (kidney trans-
plantation: 38,300 DM). Liver patients have a higher po-
tential to experience a significant gain in quality of life
than dialysis patients. On the other hand the long-term
results of patients who received a kidney transplantation
are better in terms of mortality compared to patients who
received a liver transplantation. Nevertheless, patients
with liver transplantation experience higher numbers of
QALYs gained than patients with kidney transplantation,
as the mortality of dialysis patients does not change after
transplantation (except for the operation risk). 
CONCLUSION: Liver transplantation is still a high-cost
procedure with a high cost-utility ratio compared to
other medical interventions. To avoid problems of fi-
nancing the cost of liver transplantation have to be de-
creased and/or outcomes (mortality, quality of life) must
be improved.
ECONOMIC AND OUTCOMES ISSUES OF 
PAIN MANAGEMENT
PCP1
A THREE-PHASED DECISION ANALYTIC MODEL 
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THERAPY FOR CHRONIC PAIN
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Pain management guidelines advise opioids for the man-
agement of chronic moderate to severe pain, both malig-
nant and non-malignant. Among the options for opioid
therapy, oral opioids and transdermal fentanyl offer pa-
tient convenience and cost advantages over parenteral
(e.g., IV or IT) administration. After efficacy, patient con-
venience and cost are primary criteria in selecting chronic
pain control therapy. In order to better understand the
distinctions in these criteria, an economic framework for
evaluating transdermal fentanyl and oral opioids is
needed. 
OBJECTIVE: To develop an economic framework for
evaluating transdermal fentanyl and oral opioids for
management of chronic moderate to severe malignant
and non-malignant pain. 
METHODS: Based on a systematic review of the litera-
ture, a decision analytic model was developed. It is com-
prised of three phases: titration (lasting up to several
days), stabilization (30 days), and long-term use (through
the first year). The primary outcomes are costs, quality-
adjusted life-days (QALDs), and incremental cost-utility
ratios. Probabilities of events and disutility values were
determined from clinical trials of transdermal fentanyl,
controlled release morphine, and controlled release oxy-
codone, supplemented when necessary with expert opin-
ion. Costs were derived from publicly available data. 
RESULTS: The key cost drivers are opioid price, the
probability of switching to an alternative therapy, and
the cost of treating nausea and vomiting. The primary
parameters influencing QALDs are the probability of sus-
tained pain control and the probability and disutility of
chronic constipation. 
CONCLUSION: This model may be used to guide data
collection in head-to-head clinical trials, and may be used
by individual decision-makers to inform selection of the
optimal opioid for chronic pain management.
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IMPACT OF PATIENT EDUCATION ON 
QUALITY OF LIFE IN HEADACHE TREATMENT
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1Cleveland Clinic Foundation, Cleveland, OH, USA; 2Adelman 
Headache Center, Greensboro, NC, USA
OBJECTIVE: This study compares the impact of patient
education with individualized headache management on
health-related quality of life. 
